Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

Santhosh A. Upadhyaya(St. Jude Children's Research Hospital), Amar Gajjar(St. Jude Children's Research Hospital), Daniel C. Moreira(St. Jude Children's Research Hospital), Roya Mostafavi(St. Jude Children's Research Hospital), Holly Lindsay(Baylor College of Medicine), Alberto Broniscer(St Nicholas Hospital), Kim E. Nichols, Evadnie Rampersaud, Anna Vinitsky(St. Jude Children's Research Hospital), Amy Smith(Arnold Palmer Hospital for Children), Brent A. Orr(St. Jude Children's Research Hospital), Zoltán Patay(St. Jude Children's Research Hospital), Clinton F. Stewart(St. Jude Children's Research Hospital), John R. Crawford(University of California San Diego), Lindsay Kilburn(Northwestern University), Catherine A. Billups(St. Jude Children's Research Hospital), Jason R. Myers(University of Rochester), Dolly Aguilera(Center for Cancer and Blood Disorders), Giles Robinson(St. Jude Children's Research Hospital), Olivia Campagne(St. Jude Children's Research Hospital), Sonia Partap(Boston Medical Center), Arzu Onar‐Thomas(St. Jude Children's Research Hospital), David W. Ellison(Drug Discovery Laboratory (Norway)), Ruth Tatevossian(St. Jude Children's Research Hospital), Paul Klimo(St. Jude Children's Research Hospital), Anne Bendel(Children's Minnesota), Cynthia Wetmore(Neoleukin Therapeutics (United States)), Patricia Baxter(Baylor College of Medicine)

Neuro-Oncology

June 2, 2022

Cited by 29

|Nature|2012|853

|Nature Genetics|2010|809

|Journal of Clinical Oncology|2010|657

|Nature Genetics|2014|654

|Acta Neuropathologica|2016|650

Related Papers